Davita Center Point Dialysis is a medicare approved dialysis facility center in Center Point, Alabama and it has 16 dialysis stations. It is located in Jefferson county at 2337 1st St Ne, Center Point, AL, 35215. You can reach out to the office of Davita Center Point Dialysis at (205) 520-1108. This dialysis clinic is managed and/or owned by Davita. Davita Center Point Dialysis has the following ownership type - Profit. It was first certified by medicare in February, 2008. The medicare id for this facility is 012623 and it accepts patients under medicare ESRD program.
| Name | Davita Center Point Dialysis |
|---|---|
| Location | 2337 1st St Ne, Center Point, Alabama |
| No. of Dialysis Stations | 16 |
| Medicare ID | 012623 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 2337 1st St Ne, Center Point, Alabama, 35215 | |
| (205) 520-1108 | |
News Archive
Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China today reported financial results for the three months ended March 31, 2015.
Scientists in the United States say that they have found a way to make the lethal Ebola virus harmless in the laboratory.
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
› Verified 2 days ago
| NPI Number | 1912193384 |
| Organization Name | Center Point Dialysis |
| Doing Business As | Renal Treatment Centers Southeast Lp |
| Address | 2337 1st St Ne Center Point, Alabama, 35215 |
| Phone Number | (205) 520-1108 |
News Archive
Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China today reported financial results for the three months ended March 31, 2015.
Scientists in the United States say that they have found a way to make the lethal Ebola virus harmless in the laboratory.
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 29 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 24 |
News Archive
Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China today reported financial results for the three months ended March 31, 2015.
Scientists in the United States say that they have found a way to make the lethal Ebola virus harmless in the laboratory.
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 60 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 509 |
| Percentage of adult patients getting regular hemodialysis at the center | 94 |
News Archive
Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China today reported financial results for the three months ended March 31, 2015.
Scientists in the United States say that they have found a way to make the lethal Ebola virus harmless in the laboratory.
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita Center Point Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 61 |
| Hypercalcemia patient months | 535 |
| Patients with Serumphosphor | 64 |
| Patients with Serumphosphor less than 3.5 mg/dL | 7 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 28 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 29 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 19 |
| Patients with Serumphosphor greater than 7 mg/dL | 16 |
News Archive
Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China today reported financial results for the three months ended March 31, 2015.
Scientists in the United States say that they have found a way to make the lethal Ebola virus harmless in the laboratory.
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 42 |
| Patient months included in arterial venous fistula and catheter summaries | 333 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 55 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 12 |
News Archive
Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China today reported financial results for the three months ended March 31, 2015.
Scientists in the United States say that they have found a way to make the lethal Ebola virus harmless in the laboratory.
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 48 |
| Hospitalization Rate in facility | 245.8 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 437.6 |
| Hospitalization Rate: Lower Confidence Limit | 143.8 |
News Archive
Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China today reported financial results for the three months ended March 31, 2015.
Scientists in the United States say that they have found a way to make the lethal Ebola virus harmless in the laboratory.
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita Center Point Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 35.3 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 47.3 |
| Readmission Rate: Lower Confidence Limit | 24.4 |
News Archive
Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China today reported financial results for the three months ended March 31, 2015.
Scientists in the United States say that they have found a way to make the lethal Ebola virus harmless in the laboratory.
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Davita Center Point Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .96 (As Expected) |
| SIR: Upper Confidence Limit | 2.62 |
| SIR: Lower Confidence Limit | .24 |
News Archive
Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China today reported financial results for the three months ended March 31, 2015.
Scientists in the United States say that they have found a way to make the lethal Ebola virus harmless in the laboratory.
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Davita Center Point Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 40 |
| Transfusion Rate in facility | 74 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 190.3 |
| Transfusion Rate: Lower Confidence Limit | 32.3 |
News Archive
Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China today reported financial results for the three months ended March 31, 2015.
Scientists in the United States say that they have found a way to make the lethal Ebola virus harmless in the laboratory.
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at Davita Center Point Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 269 |
| Mortality Rate in facility | 24.5 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 34.4 |
| Mortality Rate: Lower Confidence Limit | 16.8 |
News Archive
Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China today reported financial results for the three months ended March 31, 2015.
Scientists in the United States say that they have found a way to make the lethal Ebola virus harmless in the laboratory.
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
› Verified 2 days ago
Davita Center Point Dialysis Location: 2337 1st St Ne, Center Point, Alabama, 35215 Phone: (205) 520-1108 |
News Archive
Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China today reported financial results for the three months ended March 31, 2015.
Scientists in the United States say that they have found a way to make the lethal Ebola virus harmless in the laboratory.
Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced receipt of 510(k) marketing clearance from the U.S. Food and Drug Administration for its next generation peripheral artery disease (PAD) testing system.
› Verified 2 days ago